New York, June 1, 2026, 07:03 EDT
- Cabaletta Bio ended Friday at $3.78. The stock was quoted at $3.92 ahead of the open, with early volume light.
- Investors are watching for Cabaletta’s appearance at Jefferies on June 3 and for EULAR presentations set to kick off June 4.
- After the May raise, the company now has enough cash into mid-2027. Still, its latest 10-Q keeps going-concern language and mentions risks about trial execution.
Cabaletta Bio shares gained in light premarket action Monday, bouncing after drifting out of focus for some traders. The autoimmune cell-therapy firm is set to appear at a healthcare conference in two days, with key clinical data due out in London later this week.
Shares ended Friday at $3.78. Pre-market quotes showed the stock at $3.92, a 3.7% gain. Only a few thousand shares traded before the bell, so the premarket jump could fade when the Nasdaq opens.
The dates set up a busy week for Cabaletta. The company is slated for the Jefferies Global Healthcare Conference in New York on June 3. Over in London, the European Alliance of Associations for Rheumatology meeting runs June 3-6, where Cabaletta has scheduled several rese-cel presentations for June 4 and June 6.
Rese-cel is Cabaletta’s top CAR T program. CAR T stands for chimeric antigen receptor T-cell therapy, which engineers immune cells to target cells. Cabaletta is using the method in autoimmune diseases where the immune system targets body tissue.
Cabaletta Bio said in May its main RESET-Myositis group is moving ahead, and could back the company’s planned first Biologics License Application for rese-cel in 2027. A BLA is what a company files to seek U.S. approval to sell a biologic drug.
Cabaletta CEO Steven Nichtberger said the company is “well-positioned to advance rese-cel to BLA submission” thanks to recent funding. Nichtberger called out “compelling drug-free clinical responses” in pemphigus vulgaris patients who were treated without preconditioning, the chemo-style prep step usually given ahead of cell therapy. Cabaletta Bio, Inc.
‘No-preconditioning’ at center of Cabaletta stock story
Cabaletta said two out of four refractory pemphigus vulgaris patients showed drug-free responses at six months on the lowest dose. Early automated manufacturing data from two patients pointed to cell expansion and B-cell depletion matching earlier clinical supply. “If the data hold up, this approach could substantially expand access,” Chief Medical Officer David Chang said. Cabaletta Bio, Inc.
Cabaletta reported $116.6 million in cash and cash equivalents at the end of March and brought in around $141.0 million from a follow-on in May. The company said this should cover operations through mid-2027 under its current plans.
Caba’s cash burn stayed high in the first quarter. The company posted a $43.5 million net loss, and R&D spend jumped to $37.4 million from $29.0 million a year ago.
Kyverna Therapeutics said in its latest annual report the space is competitive. The company pointed to Cabaletta and Cartesian Therapeutics as rivals in cell-and-gene therapy for autoimmune diseases. Cartesian is pushing ahead with mRNA cell therapies for autoimmune disorders, running Descartes-08 trials in myasthenia gravis, lupus and myositis.
The next few months look uncertain. Cabaletta’s 10-Q notes that early results don’t always match later ones, enrollment could fall behind, manufacturing isn’t easy, and the company has said there’s “substantial doubt” it can keep operating without more cash. If the data don’t hold up or funding dries up, Cabaletta may need to cut back or pause parts of its plan. SEC
